Shire PLC Company Profile (NASDAQ:SHPG)

About Shire PLC

Shire PLC logoShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SHPG
  • CUSIP:
Key Metrics:
  • Previous Close: $181.08
  • 50 Day Moving Average: $170.69
  • 200 Day Moving Average: $181.72
  • 52-Week Range: $150.05 - $209.22
  • Trailing P/E Ratio: 145.80
  • Foreward P/E Ratio: 10.39
  • P/E Growth: 0.93
  • Market Cap: $53.94B
  • Beta: 1.53
  • Net Margins: 1.62%
  • Return on Equity: 14.81%
  • Return on Assets: 6.52%
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.25%
  • Quick Ratio: 0.57%
Additional Links:
Companies Related to Shire PLC:

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (?)
Ratings Breakdown: 3 Hold Ratings, 20 Buy Ratings
Consensus Rating:Buy (Score: 2.87)
Consensus Price Target: $227.33 (25.54% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
DateFirmActionRatingPrice TargetDetails
2/17/2017Jefferies Group LLCLower Price TargetBuy$239.00View Rating Details
2/17/2017GuggenheimReiterated RatingNeutralView Rating Details
12/23/2016BTIG ResearchReiterated RatingBuy$242.00View Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00View Rating Details
11/11/2016RBC Capital MarketsReiterated RatingOutperform$235.00View Rating Details
11/7/2016J P Morgan Chase & CoReiterated RatingOverweightView Rating Details
11/3/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyView Rating Details
10/16/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyView Rating Details
10/1/2016Piper Jaffray CompaniesSet Price TargetHold$201.00View Rating Details
9/26/2016HSBC Holdings plcDowngradeBuy -> HoldView Rating Details
6/15/2016Royal Bank Of CanadaReiterated RatingOutperformView Rating Details
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$222.00View Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightView Rating Details
5/26/2016Stifel NicolausInitiated CoverageBuy$230.00View Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyView Rating Details
5/6/2016Liberum CapitalInitiated CoverageBuyView Rating Details
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details
3/30/2016Bank of America CorpReiterated RatingBuyView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageBuyView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00View Rating Details
1/18/2016Credit Suisse GroupUpgradeBuyView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00View Rating Details
9/21/2015Barclays PLCUpgradeEqual Weight -> OverweightView Rating Details
7/16/2015Berenberg BankInitiated CoverageBuyView Rating Details
5/6/2015Kepler Capital MarketsReiterated RatingBuyView Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Shire PLC (NASDAQ:SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/16/2017Q416$3.24$3.37$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (NASDAQ:SHPG)
Current Year EPS Consensus Estimate: $15.14 EPS
Next Year EPS Consensus Estimate: $17.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20167$2.76$3.17$3.01
Q2 20164$3.05$3.23$3.13
Q3 20164$3.00$3.30$3.19
Q4 20164$3.13$3.26$3.21
Q1 20173$3.36$3.50$3.45
Q2 20173$3.62$3.77$3.69
Q3 20173$3.79$3.99$3.87
Q4 20173$3.96$4.01$3.98
(Data provided by Zacks Investment Research)


Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Annual Dividend:$0.80
Dividend Yield:0.44%
Payout Ratio:51.95% (Based on Trailing 12 Months of Earnings)
5.28% (Based on Current Year Consensus EPS Estimate)
4.59% (Based on Next Year Consensus EPS Estimate)

Dividend History for Shire PLC (NASDAQ:SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by


Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline logoShire plc (SHPG) Tops Q4 EPS by 13c (NASDAQ:SHPG) - February 17 at 7:36 PM
News IconThornburg Investment Management Inc. Sells 20292 Shares of Shire PLC (SHPG) (NASDAQ:SHPG) - February 17 at 7:36 PM logoShire PLC 4Q Earnings, Revenue Beat Street (SHPG) (NASDAQ:SHPG) - February 17 at 7:36 PM logoSHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:SHPG) - February 17 at 7:36 PM logoShire PLC 4Q Earnings, Revenue Beat Street (NASDAQ:SHPG) - February 17 at 7:36 PM
News IconRadius Health (RDUS) Stock: Gaining On Shire PLC (SHPG) Interest (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconRadius Health (RDUS) Stock: Gaining On Shire PLC (SHPG) Interest (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconRadius Health (RDUS) Stock: Gaining On Shire PLC (SHPG) Interest (NASDAQ:SHPG) - February 16 at 7:32 PM logoEARNINGS SUMMARY: Details of Shire plc Q4 Earnings Report (NASDAQ:SHPG) - February 16 at 7:32 PM logoEARNINGS SUMMARY: Details of Shire plc Q4 Earnings Report (NASDAQ:SHPG) - February 16 at 7:32 PM logoEARNINGS SUMMARY: Details of Shire plc Q4 Earnings Report (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconHow Shire plc (NASDAQ:SHPG) trades after earning announcements? (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconHow Shire plc (NASDAQ:SHPG) trades after earning announcements? (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconHow Shire plc (NASDAQ:SHPG) trades after earning announcements? (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconShire PLC (SHPG) Given Average Recommendation of "Buy" by Analysts (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconShire PLC (SHPG) Given Average Recommendation of "Buy" by Analysts (NASDAQ:SHPG) - February 16 at 7:32 PM
News IconThe The Shire PLC (SHPG) Stake Reduced by Brown Capital Management LLC (NASDAQ:SHPG) - February 16 at 7:32 PM logoShire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth (NASDAQ:SHPG) - February 16 at 7:32 PM logoShire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline (NASDAQ:SHPG) - February 16 at 7:32 PM logoShire beats Street 4Q forecasts (NASDAQ:SHPG) - February 16 at 7:32 PM logoIs this the FTSE 100’s top growth stock? (NASDAQ:SHPG) - February 16 at 7:32 PM logoDrugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High (NASDAQ:SHPG) - February 16 at 7:32 PM logoShire PLC beats by $0.13, beats on revenue (NASDAQ:SHPG) - February 16 at 8:32 AM logoWhat To Expect At Shire's FY 2016 Results - Seeking Alpha (NASDAQ:SHPG) - February 9 at 3:35 AM logoShire (SHPG) Says FTC's Challenge to ViroPharma is Wholly without Merit - (NASDAQ:SHPG) - February 9 at 3:35 AM logoShire (SHPG) Says FTC's Challenge to ViroPharma is Wholly without Merit (NASDAQ:SHPG) - February 8 at 6:07 AM logoShire Responds to U.S. Federal Trade Commission Civil Action (NASDAQ:SHPG) - February 8 at 6:07 AM logo3:44 pm Shire plc responds to U.S. Federal Trade Commission civil action against one of its subsidiaries, Shire ViroPharma (ViroPharma) (NASDAQ:SHPG) - February 8 at 6:07 AM logoFTC says Shire unit used illegal tactics to block generic competition (NASDAQ:SHPG) - February 8 at 6:07 AM
News IconShire Files 8K - Other Events (NASDAQ:SHPG) - February 2 at 1:19 AM
News IconTop Gainers of the Day: Shire plc (NASDAQ:SHPG) from Drug Manufacturers – Major (NASDAQ:SHPG) - February 1 at 1:20 AM logoPeek Under The Hood: PPH Has 23% Upside (NASDAQ:SHPG) - January 30 at 9:34 PM
News IconJennison Associates LLC Position in Shire Plc (SHPG) Trimmed by $34.49 Million as Share Price Rose (NASDAQ:SHPG) - January 30 at 9:34 PM
News IconDrug Manufacturers – Major: Shire plc (NASDAQ:SHPG) Position of the day (NASDAQ:SHPG) - January 29 at 8:26 PM
News IconLeading stocks in today’s market: Shire plc (NASDAQ:SHPG) (NASDAQ:SHPG) - January 28 at 6:34 AM logoKeeley All Cap Value Fund Comments on Shire (NASDAQ:SHPG) - January 28 at 6:34 AM
News IconEarnings in Full Force, Analysts Take Aim at Shire plc (NASDAQ:SHPG) - Wall Street Beacon (NASDAQ:SHPG) - January 27 at 3:15 AM
News IconShire Plc (SHPG) Holder National Pension Service Has Cut Its Holding as Valuation Rose - The Randolph Guide (NASDAQ:SHPG) - January 27 at 3:15 AM logoSHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events (NASDAQ:SHPG) - January 26 at 4:54 AM
News IconShire Plc (SHPG) Market Valuation Rose While Endurant Capital Management LP Has Upped Position (NASDAQ:SHPG) - January 25 at 5:31 AM
News IconAnalysts Pounding The Pavement on Shire plc (NASDAQ:SHPG): Consensus Update - Wall Street Beacon (NASDAQ:SHPG) - January 23 at 8:10 PM
News IconU.S. FDA Acknowledges Receipt of Shire’s New Drug Application for SHP465 for ADHD (NASDAQ:SHPG) - January 23 at 12:34 AM
News IconLarge Cap Drug Manufacturers – Major: Shire plc (NASDAQ:SHPG) (NASDAQ:SHPG) - January 22 at 7:33 PM logoKamada: Still Upside Ahead For This ~$6 Biopharma Stock (NASDAQ:SHPG) - January 21 at 1:09 AM logoFDA Acknowledges Receipt Of Shire' NDA For SHP465 For ADHD (NASDAQ:SHPG) - January 20 at 6:46 AM logoShire (SHPG) Says FDA Acknowledges Receipt of NDA for SHP465 for ADHD (NASDAQ:SHPG) - January 20 at 6:46 AM logoFDA receives Shire's resubmitted marketing application for ADHD candidate SHP465; action date in June (NASDAQ:SHPG) - January 20 at 6:46 AM logoU.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD (NASDAQ:SHPG) - January 20 at 6:46 AM logo7:01 am Shire announces that the FDA has acknowledged receipt of the Class 2 resubmission of an NDA for SHP465; FDA is expected to provide a decision on or around the PDUFA date of June 20, 2017 (NASDAQ:SHPG) - January 20 at 6:46 AM logoIs Shire plc a Great Stock for Value Investors? (NASDAQ:SHPG) - January 20 at 6:46 AM


What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC declared a dividend on Friday, August 5th. Shareholders of record on Friday, September 9th will be given a dividend of $0.139 per share on Friday, October 7th. The ex-dividend date of this dividend is Wednesday, September 7th.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

23 brokers have issued 12-month price objectives for Shire PLC's shares. Their forecasts range from $198.00 to $242.00. On average, they anticipate Shire PLC's stock price to reach $227.33 in the next twelve months.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
  • According to Zacks Investment Research, "Shire is a leader in the ADHD market with drugs like Vyvanse and Intuniv. The adult ADHD space is one of the largest and fastest growing segments and a potential approval of SHP465 will further strengthen Shire’s franchise. It has expanded its presence in the gastrointestinal, neuroscience and rare disease markets through strategic acquisitions. The NPS Pharma acquisition has strengthened the company's GI franchise. Moreover, Shire’s agreement to license global rights to Pfizer’s PF-00547659 will strengthen the company’s GI pipeline further. The company updated its annual guidance with expectations of $700 million of operating cost synergies from the Baxalta acquisition (completed in Jun 2016), up from the earlier projection of $500 million. Estimates have been moving up ahead of the company’s Q3 earnings results. However, headwinds remain in the form of generic competition and unfavorable currency movements." (10/21/2016)

  • Leerink Swann analysts commented, "We are modestly raising our ests after SHPG beat our 1Q sales and EPS forecast driven by solid growth in ADHD and Firazyr for hereditary angioedema. Looking ahead, we expect SHPG to outperform the market driven by solid post-BXLT guidance in 2Q, several clinical catalysts in mid-2016 and a strong lifitegrast launch in dry eye. In 1Q, exceptionally strong Vyvanse sales were a critical component to the sales growth, outpacing LP by $34m, or +7% driven by strong US volume, better than expected net pricing and international expansion. Also, SHPG delivered strong Firazyr sales, beating us by $14m or +12% and strong commercial execution on a number of other rare disease products continues to validate SHPG’s tactical portfolio shift away from reformulation drugs to becoming a leading rare disease player. We remain OP & our PT is $225/ADS (up from $221). Strong top-line keyed by several flagship brands. Beyond the 1Q strength of the ADHD franchise and Firazyr, SHPG delivered inline prints on a number of important brands including Natpara (hypoparathyroidism) sales of $16m vs. our $18, Gattex (short bowel) sales of $52m (vs. our $52m) and key enzyme replacement therapy products like Replagal (Fabry) and Elaprase (Hunter’s disease). Based on the 1Q print, we’re raising our Vyvanse ests. ~2% in 2016-23, Replagal 1-4% in 2016-23 and Firazyr 2-5% 2016-19, however offsetting that is reductions to our Natpara ests of $20-65m, as our prior above cons forecasts look too aggressive." (5/2/2016)

Who owns Shire PLC stock?

Shire PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (0.71%), Lone Pine Capital LLC (0.64%), Janus Capital Management LLC (0.41%), Orbimed Advisors LLC (0.40%), Marshall Wace LLP (0.35%) and DSM Capital Partners LLC (0.34%).

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Scharf Investments LLC, FMR LLC, Federated Investors Inc. PA, Asset Management One Co. Ltd., GLG Partners LP, Renaissance Group LLC, Brown Capital Management LLC and DSM Capital Partners LLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Lone Pine Capital LLC, Alyeska Investment Group L.P., Roystone Capital Management LP, Viking Global Investors LP, Orbimed Advisors LLC, Marshall Wace LLP and Friess Associates LLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Shire PLC stock cost?

One share of Shire PLC stock can currently be purchased for approximately $181.08.

Shire PLC (NASDAQ:SHPG) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Earnings History Chart

Earnings by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History Chart

Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Last Updated on 2/21/2017 by Staff